Kristian Brock

2.0k total citations · 1 hit paper
54 papers, 1.0k citations indexed

About

Kristian Brock is a scholar working on Neurology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Kristian Brock has authored 54 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Neurology, 13 papers in Genetics and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Kristian Brock's work include Chronic Lymphocytic Leukemia Research (13 papers), Cerebral Venous Sinus Thrombosis (13 papers) and Glaucoma and retinal disorders (8 papers). Kristian Brock is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Cerebral Venous Sinus Thrombosis (13 papers) and Glaucoma and retinal disorders (8 papers). Kristian Brock collaborates with scholars based in United Kingdom, United States and Australia. Kristian Brock's co-authors include Susan P. Mollan, Alexandra J. Sinclair, Andreas Yiangou, James Mitchell, Zerin Alimajstorovic, Rebecca Bishop, Hannah Lyons, Peter Hillmen, Daniel Slade and Francesca Yates and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Kristian Brock

52 papers receiving 983 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

2023 72 citations James Mitchell, Hannah Lyons et al. Brain profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kristian Brock United Kingdom	18	284	224	213	185	181	54	1.0k
Adrienne M. Hammill United States	19	160 0.6×	406 1.8×	389 1.8×	48 0.3×	119 0.7×	62	1.6k
Janneke Tekstra Netherlands	19	122 0.4×	37 0.2×	146 0.7×	191 1.0×	54 0.3×	56	1.3k
Jacques‐Eric Gottenberg France	20	248 0.9×	43 0.2×	185 0.9×	324 1.8×	35 0.2×	58	1.5k
Shizuyo Tsujimura Japan	16	136 0.5×	82 0.4×	89 0.4×	87 0.5×	92 0.5×	33	969
Dolly Aguilera United States	15	293 1.0×	154 0.7×	46 0.2×	51 0.3×	161 0.9×	46	676
Catherine Lai United States	16	257 0.9×	54 0.2×	316 1.5×	492 2.7×	111 0.6×	77	1.3k
Bénédicte Delcoigne Sweden	12	49 0.2×	104 0.5×	126 0.6×	93 0.5×	36 0.2×	45	554
D. Adoué France	17	144 0.5×	45 0.2×	247 1.2×	215 1.2×	195 1.1×	75	884
Karen R. Rabin United States	21	167 0.6×	84 0.4×	113 0.5×	516 2.8×	69 0.4×	109	1.6k
Loretta M. S. Lau Australia	21	119 0.4×	259 1.2×	90 0.4×	61 0.3×	169 0.9×	52	1.3k

Countries citing papers authored by Kristian Brock

Since Specialization

Citations

This map shows the geographic impact of Kristian Brock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristian Brock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristian Brock more than expected).

Fields of papers citing papers by Kristian Brock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristian Brock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristian Brock. The network helps show where Kristian Brock may publish in the future.

Co-authorship network of co-authors of Kristian Brock

This figure shows the co-authorship network connecting the top 25 collaborators of Kristian Brock. A scholar is included among the top collaborators of Kristian Brock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristian Brock. Kristian Brock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mitchell, James, Hannah Lyons, Jessica Walker, et al.. (2025). A randomized sequential cross‐over trial evaluating five purportedly ICP ‐lowering drugs in idiopathic intracranial hypertension. Headache The Journal of Head and Face Pain. 65(2). 258–268. 5 indexed citations

Homer, Victoria, Darren Barton, Kristian Brock, et al.. (2024). A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial. PLoS ONE. 19(7). e0291285–e0291285. 1 indexed citations

Patel, Amit, Kristian Brock, Daniel Slade, et al.. (2024). Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial. BMC Medical Research Methodology. 24(1). 11–11. 2 indexed citations

Grech, Olivia, James Mitchell, Hannah Lyons, et al.. (2024). Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension. Eye. 38(7). 1374–1379. 17 indexed citations

Mitchell, James, Hannah Lyons, Jessica Walker, et al.. (2023). The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 146(5). 1821–1830. 72 indexed citations breakdown →

Sadnicka, Anna, Lorenzo Rocchi, Anna Latorre, et al.. (2022). A Critical Investigation of Cerebellar Associative Learning in Isolated Dystonia. Movement Disorders. 37(6). 1187–1192. 10 indexed citations

Mitchell, James, Susan P. Mollan, Jessica Walker, et al.. (2022). A randomised controlled, trial of the GLP-1 receptor agonist exenatide in idiopathic intracranial hypertension. Journal of Neurology Neurosurgery & Psychiatry. 93(6). A98.2–A98. 2 indexed citations

Mitchell, James, Hannah Lyons, Jessica Walker, et al.. (2022). Evaluation of diurnal and postural intracranial pressure employing telemetric monitoring in idiopathic intracranial hypertension. Fluids and Barriers of the CNS. 19(1). 85–85. 20 indexed citations

Mollan, Susan P., James Mitchell, Andreas Yiangou, et al.. (2022). Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension. Neurology. 99(11). e1090–e1099. 33 indexed citations

10.

Brock, Kristian, et al.. (2021). Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. BMC Cancer. 21(1). 777–777. 9 indexed citations

11.

Mollan, Susan P., Victoria Homer, Simon Gates, Kristian Brock, & Alexandra J. Sinclair. (2021). One Eye or Two: Statistical Considerations in Ophthalmology With a Focus on Interventional Clinical Trials. Journal of Neuro-Ophthalmology. 41(4). 421–423. 4 indexed citations

12.

Hillmen, Peter, Rebecca H. Boucher, Nichola Webster, et al.. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood. 136(Supplement 1). 17–18. 13 indexed citations

13.

Middleton, Gary, Kristian Brock, Joshua Savage, et al.. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet Respiratory Medicine. 8(9). 895–904. 113 indexed citations

14.

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 37(30). 2722–2729. 180 indexed citations

15.

Hill, Lisa J., Richard J. A. Moakes, Chairut Vareechon, et al.. (2018). Sustained release of decorin to the surface of the eye enables scarless corneal regeneration. npj Regenerative Medicine. 3(1). 23–23. 50 indexed citations

16.

Munir, Talha, Andy C. Rawstron, Kristian Brock, et al.. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. British Journal of Haematology. 181. 34–35. 1 indexed citations

17.

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2018). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. Blood. 132(Supplement 1). 182–182. 24 indexed citations

18.

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2017). The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.. Haematologica. 102. 311–311. 4 indexed citations

19.

Hillmen, Peter, Talha Munir, Andy C. Rawstron, et al.. (2017). Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood. 130. 428–428. 25 indexed citations

20.

Glasbey, James, et al.. (2017). Recommendations for Randomised Trials in Surgical Oncology. Clinical Oncology. 29(12). 799–810. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact